BCD-132

BIOLOGICAL2 trials

Sponsors

Biocad

Conditions

Multiple Sclerosis

Phase 1

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

CompletedNCT03551275

BiocadMultiple Sclerosis

Start: 2018-02-22End: 2019-03-28Updated: 2021-09-08

Phase 3

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

CompletedNCT05385744

BiocadMultiple Sclerosis

Start: 2021-04-05End: 2023-09-29Updated: 2024-11-25

Related Papers

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

S S Korsakov Journal of Neurology and Psychiatry2024-04-238 citations